CME Information

Target audience

This educational activity is intended for physicians, and nurses involved in the care of patients
with chronic constipation or IBS-C, and other healthcare professionals with an interest in
learning more about the latest data in this field.

Learning objectives

At the conclusion of this activity, participants should be able to:

  • Explain the underlying, multi-factorial mechanisms of constipation
  • Recognize the value of a symptom-led differential diagnosis of chronic constipation
    and IBS-C and the optimal use of diagnostic testing
  • Evaluate therapeutic options for patients with constipation.

CME/CE-certification

FOR PHYSICIANS

This Activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of CME Consultants and Strategic Consultants International. CME Consultants is accredited by the ACCME to provide continuing medical education for physicians.

CME Consultants, designates this educational activity for a maximum of 2.0 AMA PRA Category 1
Credit(s)TM.
Physicians should only claim credit commensurate with the extent of their participation in the activity.

FOR NURSES

CME Consultants, is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
CME Consultants designates this activity for 2.0 contact hours. Participants should claim only those contact hours actually spent in the education activity.
In order to receive credit for this activity, each participant must complete the evaluation and certificate request form. Certificates will be mailed to activity participants in approximately four to six weeks after receipt of the completed evaluation form and sign-in sheet.

FOR NURSE PRACTITIONERS

This program has been approved for 2.0 contact hours of continuing education by the American Academy of Nurse Practitioners. Program ID 0801053

January 10, 2008 through January 9, 2009

Faculty disclosures

In direct response to the September 2004 Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, CME Consultants issued a conflict of interest policy dated January 2, 2005. The policy states that the disclosure of potential financial conflicts of interest within the last 12 months must be made and resolved prior to date of the CME/CE activity where commercial support grants are to be used to fund the activity. The following conflicts have been managed and resolved through CME Consultants’ Independent Review Committee. Our intent is to assist learners in assessing the potential for bias in information that is presented during this CME/CE activity.

The faculty is also aware it is their responsibility to inform the audience if discussion of any non-FDA approved uses of pharmaceuticals, medical equipment, prostheses, etc. will be included in their presentation.

Name Company Relationship
Lawrence J. Brandt EZM, Novartis Pharmaceuticals Speaker / Honorarium
John F. Johanson GlaxoSmithKline, Prometheus, Salix, Sucampo Pharmaceuticals, Takeda Pharmaceuticals North America Speaker / Honorarium
Boehringer Ingelheim, Prometheus, Salix, Sucampo Pharmaceuticals, Takeda Pharmaceuticals North America, Theravance Inc. Consulting
Sucampo Pharmaceuticals, Takeda Pharmaceuticals North America Honorarium
Sucampo Pharmaceuticals Stock options
Satish S.C. Rao Forest Laboratories, Johnson & Johnson, Novartis Pharmaceuticals, SmartPill, Takeda Pharmaceuticals North America, Theravance Inc. Consultant / Advisory Board
AstraZeneca, Janssen, Novartis Pharmaceuticals, Salix, TAP Pharmaceuticals, Takeda Pharmaceuticals North America Speaker Bureau
SmartPill, Sucampo Pharmaceuticals, Takeda Pharmaceuticals North America Unrestricted grants
Lawrence R. Schiller Abbott Immunology, McNeil Pharmaceuticals, Napo Pharmaceuticals, Novartis Pharmaceuticals, Prometheus Labs, Santarus, Sucampo Pharmaceuticals, Takeda Pharmaceuticals North America, UCB Pharmaceuticals Advisory Board
Abbott Immunology, AstraZeneca, Novartis Pharmaceuticals, Prometheus Labs, Santarus, Sucampo Pharmaceuticals, Takeda Pharmaceuticals North America Consultant / Speaker

The planners, managers and anyone in a position to control the content of CME activities are also required to report any conflicts of interest. The following conflicts have been managed and resolved through CME Consultants’ Independent Review Committee.

Name of planner or manager Company and Relationship
Samantha Mattiucci, PharmD
CME Consultants
Nothing to disclose
Joyce M. Anderson, Project Director
CME Consultants
Nothing to disclose
Ian Morgan, Project Director
Strategic Consultants International
Nothing to disclose
Ailsa Stewart, Senior Project Manager
Strategic Consultants International
Nothing to disclose